Claficapavir is primarily investigated for its application in the treatment of HIV infections. It functions as a long-acting capsid inhibitor, targeting the viral capsid protein to disrupt the virus's lifecycle. This mechanism makes it a promising candidate for use in combination antiretroviral therapy (ART) to enhance treatment efficacy and reduce dosing frequency. Its long-acting properties are particularly beneficial for improving patient adherence and managing HIV in resource-limited settings. Additionally, Claficapavir is being explored for its potential in pre-exposure prophylaxis (PrEP) to prevent HIV transmission in high-risk populations. Ongoing research aims to further validate its safety and effectiveness in clinical settings.